Compare FOLD & CSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOLD | CSQ |
|---|---|---|
| Founded | 2002 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.1B |
| IPO Year | 2007 | N/A |
| Metric | FOLD | CSQ |
|---|---|---|
| Price | $14.19 | $19.19 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $29.79 | N/A |
| AVG Volume (30 Days) | ★ 14.8M | 220.3K |
| Earning Date | 11-04-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.53% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $598,704,000.00 | N/A |
| Revenue This Year | $21.49 | N/A |
| Revenue Next Year | $18.25 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.28 | N/A |
| 52 Week Low | $5.51 | $12.50 |
| 52 Week High | $14.36 | $16.45 |
| Indicator | FOLD | CSQ |
|---|---|---|
| Relative Strength Index (RSI) | 91.10 | 56.05 |
| Support Level | $10.64 | $18.67 |
| Resistance Level | $11.14 | $19.44 |
| Average True Range (ATR) | 0.36 | 0.21 |
| MACD | 0.28 | -0.01 |
| Stochastic Oscillator | 96.46 | 67.53 |
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's objective is to provide total return through a combination of capital appreciation and current income. Its investment portfolio comprises equities, convertible securities, and high-yield corporate bonds.